Brokerages expect Trevena Inc (NASDAQ:TRVN) to post earnings per share of ($0.08) for the current quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. Trevena reported earnings per share of ($0.06) during the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The firm is expected to announce its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Trevena will report full year earnings of ($0.27) per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of ($0.33) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Trevena.
Trevena (NASDAQ:TRVN) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Sigma Advisers LP grew its holdings in shares of Trevena by 35.3% in the 4th quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 16,400 shares during the period. Alpine Global Management LLC acquired a new position in shares of Trevena in the 1st quarter valued at $31,000. Geode Capital Management LLC grew its holdings in shares of Trevena by 38.9% in the 4th quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 133,510 shares during the period. Vanguard Group Inc. grew its holdings in shares of Trevena by 11.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock valued at $4,032,000 after buying an additional 403,060 shares during the period. Finally, BlackRock Inc. grew its holdings in shares of Trevena by 1.9% in the 2nd quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 49,900 shares during the period. 22.88% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:TRVN opened at $0.89 on Friday. Trevena has a 1 year low of $0.38 and a 1 year high of $3.58. The firm has a 50 day moving average of $0.95 and a 200-day moving average of $1.27. The company has a current ratio of 3.77, a quick ratio of 3.77 and a debt-to-equity ratio of 0.19.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.